Health

Morning Break: Breast Implant Ban in France; Praluent Price Cut; Lego Iron Teen

Note that some links may require subscriptions.

On Friday, French regulatory authorities recommended a ban on Allergan textured breast implants, citing concerns about breast implant-associated anaplastic large cell lymphoma. (NBC News)

Sanofi and Regeneron announced a 60% list-price cut on PCSK9 inhibitor alirocumab (Praluent) to $5,850 per year — the same as what Amgen now charges for its rival drug, evolocumab (Repatha). (Reuters)

One pediatrician shares her experience about how she convinced anti-vax parents to eventually vaccinate their children. (CNN)

And now, meet kids of anti-vaxxers who are circumventing their parents and getting vaccinated themselves. (Washington Post)

A special high school program in Dallas is helping students to role-play about depression. (AP)

With the ultimate fate of Roe v. Wade uncertain, some states are looking to restrict abortion while others are legislating protections for the procedure. (New York Times)

The “craziest experiment possible?” These researchers went for it in an attempt to see if human diet drugs would quell mosquitoes’ bloodlust. (NPR)

At an Immigration and Customs Enforcement detention facility, seven adults have been diagnosed with mumps. (Reuters)

Good news — doctors likely won’t be replaced by medical chatbots anytime soon. (CNBC)

Psychologists delve into the many factors that contribute into the making of a school shooter. (NPR)

Hospitals report injuries from the latest stupid Internet stunt — the “boiling water challenge.” (Newsweek)

Some of the science behind why paper cuts hurt so much. (Fox News)

When born without a right forearm, this teenager decided to ‘Tony Stark’ his own — out of Lego’s! (CNET)

Morning Break is a daily guide to what’s new and interesting on the Web for healthcare professionals, powered by the MedPage Today community. Got a tip? Send it to us: MPT_editorial@everydayhealthinc.com

2019-02-11T09:30:00-0500


Source link
Show More

Leave a Reply

Back to top button
Skip to toolbar